IEQ Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

IEQ Capital’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$123K	Hold	40,048	–	–	﹤0.01%	1772
2025 Q4	$164K	Buy	40,048 +6,000	+18%	+$29.7K	﹤0.01%	1722
2025 Q3	$166K	Hold	34,048	–	–	﹤0.01%	1709
2025 Q2	$172K	Sell	34,048 -19,180	-36%	-$94.2K	﹤0.01%	1643
2025 Q1	$282K	Buy	53,228 +19,180	+56%	+$140K	﹤0.01%	1217
2024 Q4	$230K	Hold	34,048	–	–	﹤0.01%	1142
2024 Q3	$224K	Hold	34,048	–	–	﹤0.01%	1027
2024 Q2	$255K	Hold	34,048	–	–	﹤0.01%	847
2024 Q1	$339K	Hold	34,048	–	–	﹤0.01%	739
2023 Q4	$336K	Buy	34,048 +7,168	+27%	+$51.1K	0.01%	701
2023 Q3	$206K	Buy	26,880 +8,960	+50%	+$89.4K	﹤0.01%	832
2023 Q2	$134K	Hold	17,920	–	–	﹤0.01%	834
2023 Q1	$120K	Hold	17,920	–	–	﹤0.01%	845
2022 Q4	$138K	Hold	17,920	–	–	﹤0.01%	756
2022 Q3	$191K	Buy	+17,920	New	+$181K	0.01%	775

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IEQ Capital's RXRX Position: Q1 2026 in Review

IEQ Capital held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 40,048 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #1772.

IEQ Capital first reported a position in RXRX in Q3 2022 and has held it in 15 quarters since. The position peaked at $339K in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

IEQ Capital held 40,048 shares of Recursion Pharmaceuticals worth $123K as of Q1 2026.
IEQ Capital left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
Recursion Pharmaceuticals made up ﹤0.01% of IEQ Capital's portfolio in Q1 2026, its #1772 holding.
IEQ Capital first reported a position in Recursion Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
IEQ Capital's Recursion Pharmaceuticals position peaked at $339K in Q1 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on IEQ Capital's 13F filing for Q1 2026, filed 15 May 2026.